joint ULB-UNIL PhD summer course in cancer biology, Sept 12-16, Brussels
March 16th 2022 - 10:40
Dr. Jean Yannis Perentes, UNIL
Prof. Etienne Meylan, ULB
Where and when?
This course takes place in two consecutive years and participants are expected to attend both years.
In 2022, the course will be at ULB in the new Jules Bordet Institute in Brussels from Monday Sept 12th until
Friday Sept 16th. The participants coming from Lausanne will travel by train on Sept 11th and Sept 17th.
In 2023, the course will be at UNIL; the precise location and dates will be communicated later.
Goals of the 2022-2023 joint ULB-UNIL Summer courses in Cancer Biology:
1) To learn about the latest...
Séance solennelle de remise des insignes de Doctorat Honoris Causa 2022
March 08th 2022 - 11:01
Séance solennelle de remise des insignes de Doctorat Honoris Causa à Madame Katalin Karikó professeure à l’Université de Pennsylvanie et figure majeure de la vaccination, pour ses recherches innovantes en thérapie génique basée sur l’ARN messager.
Le jeudi 24 mars à 17h
Campus Erasme, bâtiment W, auditoire Lise Thiry
rue Meylemeersch 22, 1070 Bruxelles
Type 2 Immunity in Early Life 9 & 10 May 2022, Liege, Belgium
January 07th 2022 - 11:50
Gestation through to weaning from our mothers is considered to be a time when immune systems show a bias to Type 2 immunity. The significance of this for mothers and offspring health during pregnancy, nursing and in later life is being recognised as being a key determinant of both positive and negative, short and long term health trajectories.
In this meeting we will present some of the latest insights into how this early life immune status influences important health scenarios and how these effects may be extended into later life once direct maternal offspring interactions have been...
EMBO workshop - Pathogen Immunity and Signaling / 04 - 08 April 2022 / Saint-Malo, France
November 22nd 2021 - 14:23
About the Workshop
Infectious diseases are one of the most important threats to human health, as exemplified by the recent coronavirus pandemic. Understanding the biology of host responses to pathogens is paramount to the development of new treatment strategies. The goal of this workshop is to bring together experts working on different aspects of the immune system and its response to infectious microorganisms. This includes:
(i) pattern-recognition receptors that detect the presence of pathogens,
(ii) the role of ubiquitin in immune signalling, and
(iii) animal models, pathogenesis and...
New publication on the role of ACOD1 in Brucella infection
September 16th 2021 - 14:36
In this article published in PLOS Pathogens, Aurore Demars from the group of Eric Muraille explores the role of aconitate decarboxylase 1 gene (Acod1; also known as Immune responsive gene 1) in the control of pulmonary Brucella infection in mouse. They observe that Acod1 is upregulated in murine alveolar macrophages in response to Brucella infection and that Acod1 deficient mice display a higher bacterial load in their lungs than control mice, demonstrating that Acod1 participates in the control of pulmonary Brucella infection. The ACOD1 enzyme is mostly produced in mitochondria of...
CIVIS course: Technical innovations in basic and translational research: Applications to Immunology-Oncology (IO)
September 14th 2021 - 11:39
The Institute of Cancer and Immunology (ICI) offers to Master and PhD students the opportunity to follow a mixed international mobility program on the theme of "Technical innovations in basic and translational research: Applications to Immunology-Oncology (IO)" within the universities of the CIVIS alliance. Both virtual mobility in the form of e-learning (webinars and videos) and 5-days physical mobility in high-tech scientific platforms, will allow students to discover or to deepen their skills in Immuno-Oncology. REGISTRATION closed on September 30!
Save the date: BCG Symposium Lille
September 06th 2021 - 10:32
2021 is the year of the 100th anniversary of the first administration of the Bacillus Calmette - Guérin (BCG) to a human being. It was the start of a long journey of the world’s most widely used vaccine and is today the oldest vaccine still in use. As of today, more than 4 billion children have been vaccinated with BCG to protect them against tuberculosis. However, over the years it became apparent that BCG has also interesting non-specific effects. As such, it is able to provide protection against various heterologous infectious and non-infectious diseases and is widely used to treat...
Save the date: Keystone (Virtual) Symposium on Maternal-Fetal Newborn Immunity: October 28-29
September 06th 2021 - 10:21
Worldwide, deaths from adverse pregnancy outcomes of preterm birth (PTB) and stillbirth (SB) represent the longest, deadliest pandemic in human history. Neonatal infection (e.g. sepsis) is the main cause of death for children under 5 years; with premature babies being especially susceptible to infection. While the final common pathway for SB, PTB and neonatal sepsis is associated with aberrant inflammation in the maternal-fetal dyad, lack of insight into the underlying mechanisms has hampered identification of effective upstream preventative or downstream therapeutic interventions. A focus on...
New Pre-print: Functional reprogramming of monocytes in acute and convalescent severe COVID-19 patients
August 20th 2021 - 11:18
Considerable advances have been made in the last months in understanding the contribution of the immune system to the pathology induced by SARS-CoV2. Here, Elisa BRAUNS from the group of Stanislas Goriely assessed the short and long-term impact of the infection on the function and the molecular features of circulating monocytes. They demonstrate that severe infection is associated with major alterations of the capacity of monocytes to produce cytokines in response to stimulation by various TLR ligands. However, this immune paralysis was not persistent as it was followed in the next months by...
New publication on the role of T follicular helper cells in breast cancer
August 20th 2021 - 11:02
In this article published in the Journal of Clinical Investigation
, the group of Karen Willard-Gallo explores the mechanisms leading to the formation of active Tertiary Lymphoid Structures (TLS) in breast cancer. Analysis of active versus inactive TLS in untreated patients revealed that the former are associated with positive clinical outcomes. They explore the role of tumor-infiltrating Follicular Helper (Tfh) and Regulatory T cells (Tfr) in this process and show that these cells represent a potential key target of PD1/PDL1 blockade.